Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
Recruiting now · Phase 1
Conditions studied: Cervical Cancer, Breast Cancer, Colon Cancer, NSCLC, mCRPC (Metastatic Castration-resistant Prostate Cancer), Glioblastoma, Nonsmall Cell Lung Cancer
In brief
A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of 212Pb-DOTAM-GRPR1 in Adult Participants with Recurrent or Metastatic GRPR-expressing Tumors
Key facts
- Study ID
- NCT05283330
- Run by
- Orano Med Theranostics, SAS
- People needed
- 48
- Starts
- 2022-12-22
- Expected to finish
- 2032-05-01
- Last updated by the study team
- 2026-06-11
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- UK Markey Cancer Center — Lexington, Kentucky, United States (enrolling)
- Nebraska Cancer Specialists (Midwest Cancer Center - Legacy) — Omaha, Nebraska, United States (enrolling)
- XCancer Omaha / Urology Cancer Center — Omaha, Nebraska, United States (enrolling)
- Advanced Molecular Imaging and Therapy — Glen Burnie, Maryland, United States (enrolling)
- University of Pittsburg Medical Center (UPCM) — Pittsburgh, Pennsylvania, United States
- University of Iowa Health Care — Iowa City, Iowa, United States
- United Theranostics - Chesapeake — Glen Burnie, Maryland, United States
- Northwestern University Robert H Lurie Medical Research — Chicago, Illinois, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.